Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents

Xavier de Leval, Thibaut Dassesse, Jean-Michel Dogné, David Waltregny, Akeila Bellahcène, Valérie Benoit, Bernard Pirotte, Vincent Castronovo

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor (VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4% inhibition, respectively) when used at the final concentration of 10 microM. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca(2+) pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F(2)) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl]urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2-p-toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.
Original languageEnglish
Pages (from-to)1057-67
Number of pages11
JournalThe Journal of pharmacology and experimental therapeutics
Volume318
Issue number3
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Thromboxane A2
Angiogenesis Inhibitors
Thromboxanes
Endothelial Cells
Cell Movement
torsemide
Cell Adhesion
Vascular Endothelial Growth Factor A
Urea
Cell Survival
Blood Platelets
Cell Migration Inhibition
Thromboxane-A Synthase
Sodium Potassium Chloride Symporter Inhibitors
Cyclooxygenase 1
Chemotactic Factors
Prostaglandins F
Chemotaxis
Cyclooxygenase 2
Platelet Aggregation

Keywords

  • Angiogenesis Inhibitors
  • Animals
  • Calcium
  • Cell Adhesion
  • Cell Movement
  • Cells, Cultured
  • Cyclooxygenase Inhibitors
  • Endothelial Cells
  • Humans
  • Hydrazines
  • Male
  • Platelet Aggregation
  • Rats
  • Rats, Wistar
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Sulfonamides
  • Thromboxane A2
  • Thromboxane-A Synthase

Cite this

de Leval, Xavier ; Dassesse, Thibaut ; Dogné, Jean-Michel ; Waltregny, David ; Bellahcène, Akeila ; Benoit, Valérie ; Pirotte, Bernard ; Castronovo, Vincent. / Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. In: The Journal of pharmacology and experimental therapeutics. 2006 ; Vol. 318, No. 3. pp. 1057-67.
@article{13d15610bf704bb09b0848f874b1977d,
title = "Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents",
abstract = "Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor (VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4{\%} inhibition, respectively) when used at the final concentration of 10 microM. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca(2+) pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F(2)) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl]urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2-p-toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.",
keywords = "Angiogenesis Inhibitors, Animals, Calcium, Cell Adhesion, Cell Movement, Cells, Cultured, Cyclooxygenase Inhibitors, Endothelial Cells, Humans, Hydrazines, Male, Platelet Aggregation, Rats, Rats, Wistar, Receptors, Thromboxane A2, Prostaglandin H2, Sulfonamides, Thromboxane A2, Thromboxane-A Synthase",
author = "{de Leval}, Xavier and Thibaut Dassesse and Jean-Michel Dogn{\'e} and David Waltregny and Akeila Bellahc{\`e}ne and Val{\'e}rie Benoit and Bernard Pirotte and Vincent Castronovo",
year = "2006",
month = "9",
doi = "10.1124/jpet.106.101188",
language = "English",
volume = "318",
pages = "1057--67",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

de Leval, X, Dassesse, T, Dogné, J-M, Waltregny, D, Bellahcène, A, Benoit, V, Pirotte, B & Castronovo, V 2006, 'Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents', The Journal of pharmacology and experimental therapeutics, vol. 318, no. 3, pp. 1057-67. https://doi.org/10.1124/jpet.106.101188

Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. / de Leval, Xavier; Dassesse, Thibaut; Dogné, Jean-Michel; Waltregny, David; Bellahcène, Akeila; Benoit, Valérie; Pirotte, Bernard; Castronovo, Vincent.

In: The Journal of pharmacology and experimental therapeutics, Vol. 318, No. 3, 09.2006, p. 1057-67.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents

AU - de Leval, Xavier

AU - Dassesse, Thibaut

AU - Dogné, Jean-Michel

AU - Waltregny, David

AU - Bellahcène, Akeila

AU - Benoit, Valérie

AU - Pirotte, Bernard

AU - Castronovo, Vincent

PY - 2006/9

Y1 - 2006/9

N2 - Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor (VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4% inhibition, respectively) when used at the final concentration of 10 microM. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca(2+) pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F(2)) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl]urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2-p-toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.

AB - Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor (VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4% inhibition, respectively) when used at the final concentration of 10 microM. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca(2+) pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F(2)) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl]urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2-p-toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.

KW - Angiogenesis Inhibitors

KW - Animals

KW - Calcium

KW - Cell Adhesion

KW - Cell Movement

KW - Cells, Cultured

KW - Cyclooxygenase Inhibitors

KW - Endothelial Cells

KW - Humans

KW - Hydrazines

KW - Male

KW - Platelet Aggregation

KW - Rats

KW - Rats, Wistar

KW - Receptors, Thromboxane A2, Prostaglandin H2

KW - Sulfonamides

KW - Thromboxane A2

KW - Thromboxane-A Synthase

U2 - 10.1124/jpet.106.101188

DO - 10.1124/jpet.106.101188

M3 - Article

C2 - 16720756

VL - 318

SP - 1057

EP - 1067

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 3

ER -